Updated:
HEALTHCAP VII ADVISOR AB
HealthCap VII Advisor AB serves as the dedicated advisory entity for the seventh fund vintage of HealthCap, a Stockholm-founded venture capital firm that...
HEALTHCAP VII ADVISOR AB
HealthCap VII Advisor AB serves as the dedicated advisory entity for the seventh fund vintage of HealthCap, a Stockholm-founded venture capital firm that began investing in life sciences in 1996. The parent firm has consistently raised sector-specialist vehicles — HealthCap VII closed at approximately €370 million in 2016, one of the largest Nordic life science funds at the time (per Medtech Insight, 2016). The advisors operating the fund are typically managing partners and senior investment professionals from the HealthCap organization, a team built around clinicians and researchers who transitioned into venture, reflecting a thesis that operational and scientific fluency wins proprietary access. HealthCap VII invests primarily in biotechnology, medical devices, and digital health, focusing on development-stage companies in Europe that require capital to reach regulatory milestones or US market entry. Its capital typically goes into Series B through crossover rounds, supporting drug and device platforms from preclinical validation through phase II clinical trials. The firm's portfolio includes companies such as Aprea Therapeutics, a p53-focused oncology biotech that listed on Nasdaq Stockholm; Wilson Therapeutics, which was acquired by Alexion for $855 million after a successful phase III trial in Wilson disease; and Calliditas Therapeutics, the IgA nephropathy specialist that secured US FDA approval for Tarpeyo (per public regulatory filings, 2021–2023). These exits illustrate the advisor's core function: translating Scandinavian basic science into globally competitive assets. The fund's team, operating from Stockholm and maintaining active board seats across its portfolio, typically counts fewer than 15 investment professionals, making it one of the more concentrated life science teams in the Nordic region (public record). HealthCap VII Advisor AB does not maintain a permanent presence outside Sweden, though portfolio companies are distributed across the UK, Switzerland, and US biotech hubs. The firm's model relies heavily on its network within the Karolinska Institute, Europe's largest medical academic research center, which has served as a consistent deal origination engine and differentiator against generalist technology funds that drift into biotech. Structurally, HealthCap VII Advisor AB is the management company and investment advisor, legally separate from the fund vehicle, a standard Nordic private equity construct designed to isolate advisory liability. The firm's GPs historically co-invest substantial personal capital alongside limited partners. This alignment structure, combined with an exclusively life sciences mandate spanning multiple decades — past cycles that killed many generalist biotech investors — makes HealthCap's architecture a narrow but deep bet on translating European academic IP into therapies.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Sweden
City
Stockholm
Corporate office
Stockholm, Sweden
Sector focus
Frequently asked questions
Who makes investment decisions at HealthCap VII?
Investment decisions are made by the managing partners of HealthCap, who serve as advisors to the fund through HealthCap VII Advisor AB. The partnership is composed of medical doctors and PhDs who combine clinical and scientific backgrounds with decades of venture experience. Their expertise allows them to evaluate drug and device platforms at the molecular and clinical trial design level, which is central to the firm's reputation for high-conviction, board-intensive investments.
How does HealthCap VII source its deal flow?
The firm sources heavily from the Karolinska Institute and connected Nordic academic research hospitals, where its partners have maintained decades-long relationships with scientists and clinician-researchers. This academic origination model gives HealthCap VII early visibility into preclinical work and first-in-human trial data before it reaches broader investor awareness. The firm's track record of spinning out Karolinska-sourced assets into publicly listed and acquired companies reinforces this proprietary pipeline.
Does HealthCap invest outside of Europe?
HealthCap VII invests primarily in European-originated companies, often those seeking to enter the US market for FDA approval or strategic partnering. While the firm does not run a dedicated US office, many portfolio companies establish a US clinical or commercial presence post-investment. The firm's network of co-investors, including US crossover funds and large pharma venture arms, provides the bridge between European science and US market execution.
What is the relationship between HealthCap VII Advisor AB and the HealthCap fund family?
HealthCap VII Advisor AB is the legal advisory entity that provides investment management services exclusively to the HealthCap VII fund. It is separate from both the fund's limited partnership vehicle and earlier or later vintage HealthCap funds. Each HealthCap fund generation typically has a distinct advisor entity, reflecting the progression of the partnership and the specific regulatory and fiscal structure required for each vintage's investors.
What investment stages does HealthCap VII target?
The fund focuses on development-stage life science investing, typically entering at Series B or later when a company has generated human proof-of-concept data. HealthCap VII also participates in crossover rounds, supporting portfolio companies as they approach regulatory milestones and public listings. The firm avoids seed-stage discovery exposure, preferring to commit capital once therapeutic or device hypotheses are validated in clinical settings.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: